- Home
- LGVN vs CMMB Comparison
LGVN vs CMMB Comparison
Compare LGVN & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGVN
- CMMB
- Stock Information
- Founded
- LGVN 2014
- CMMB 2004
- Country
- LGVN United States
- CMMB Israel
- Employees
- LGVN N/A
- CMMB N/A
- Industry
- LGVN Medicinal Chemicals and Botanical Products
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- LGVN Health Care
- CMMB Health Care
- Exchange
- LGVN Nasdaq
- CMMB Nasdaq
- Market Cap
- LGVN 16.4M
- CMMB 13.7M
- IPO Year
- LGVN 2021
- CMMB N/A
- Fundamental
- Price
- LGVN $0.89
- CMMB $3.50
- Analyst Decision
- LGVN Strong Buy
- CMMB Strong Buy
- Analyst Count
- LGVN 2
- CMMB 2
- Target Price
- LGVN $6.50
- CMMB $26.50
- AVG Volume (30 Days)
- LGVN 399.0K
- CMMB 214.4K
- Earning Date
- LGVN 11-11-2025
- CMMB 11-13-2025
- Dividend Yield
- LGVN N/A
- CMMB N/A
- EPS Growth
- LGVN N/A
- CMMB N/A
- EPS
- LGVN N/A
- CMMB N/A
- Revenue
- LGVN $2,073,000.00
- CMMB N/A
- Revenue This Year
- LGVN N/A
- CMMB N/A
- Revenue Next Year
- LGVN N/A
- CMMB N/A
- P/E Ratio
- LGVN N/A
- CMMB N/A
- Revenue Growth
- LGVN 68.67
- CMMB N/A
- 52 Week Low
- LGVN $0.63
- CMMB $2.39
- 52 Week High
- LGVN $2.48
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- LGVN 48.25
- CMMB 76.10
- Support Level
- LGVN $0.73
- CMMB $2.60
- Resistance Level
- LGVN $0.82
- CMMB $2.79
- Average True Range (ATR)
- LGVN 0.03
- CMMB 0.16
- MACD
- LGVN 0.02
- CMMB 0.02
- Stochastic Oscillator
- LGVN 94.35
- CMMB 90.50
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.